Evaluation and Predictive Value of Genetic Polymorphisms in the Management of Hormonal Treatment of Prostate Cancer (Feel+)
Sponsor: Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Listed as NCT02440802, this observational or N/A phase trial focuses on Prostate Cancer and remains ongoing. Sponsored by Cliniques universitaires Saint-Luc- Université Catholique de Louvain, it has been updated 12 times since 2013, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
12 versions recorded-
Sep 2025 — Present [monthly]
Unknown
-
Sep 2024 — Sep 2025 [monthly]
Unknown
-
Jul 2024 — Sep 2024 [monthly]
Unknown
Status: Unknown Status → Unknown
-
Dec 2021 — Jul 2024 [monthly]
Unknown Status
-
Jan 2021 — Dec 2021 [monthly]
Unknown Status
▶ Show 7 earlier versions
-
Nov 2020 — Jan 2021 [monthly]
Unknown Status
-
Nov 2018 — Nov 2020 [monthly]
Unknown Status
Status: Recruiting → Unknown Status
-
Jun 2018 — Nov 2018 [monthly]
Recruiting
-
May 2018 — Jun 2018 [monthly]
Recruiting
-
Apr 2018 — May 2018 [monthly]
Recruiting
Phase: NA → None
-
Aug 2017 — Apr 2018 [monthly]
Recruiting NA
-
Jan 2017 — Aug 2017 [monthly]
Recruiting NA
First recorded
Apr 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
- Ferring Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aalst, Belgium , Antwerp, Belgium , Brussels, Belgium , Dendermonde, Belgium , Hasselt, Belgium , Ieper, Belgium , La Louvière, Belgium , Liège, Belgium , Malle, Belgium , Merksem, Belgium and 7 more locations